小児非ホジキンリンパ腫の治療成績 : 九州・山口小児がん研究グループKYCCSG NHL-89, 96  [in Japanese] Treatment outcome of non-Hodgkin lymphoma in childhood : KYCCSG NHL-89, 96  [in Japanese]

Access this Article

Author(s)

Abstract

KYCCSGでは1989年から小児NHLに対して継続する二つの治療研究NHL-89, NHL-96を施行した。当時,小児NHLはdiffuse large cell lymphoma (DLC), lymphoblastic lymphoma (LBL), small non-cleaved lymphomaの組織型に分類されており,本研究ではDLC, LBLを対象とした。NHL-89に42例(DLC: 15例,LBL: 27例),NHL-96に34例(DLC: 8例,LBL: 26例)が登録された。DLCにはMTX大量投与を含む寛解導入療法後に,MTX中等量投与を反復した。LBLにはPSL, VCR, CPM, ADR (THP-ADR)による寛解導入療法後に強化療法,頭蓋照射を含むCNS再発予防を行い,維持療法はPSL, VCR, CPM, 6-MPなどによる多剤でのブロック治療とした。全体の5年EFSはNHL-89が76.2±6.6%,NHL-96が67.7±8.0%であり,過去の治療研究NHL-858と比較して成績の向上に成功した。

Two consecutive treatment protocols, NHL-89 and NHL-96, for pediatric diffuse large cell lymphoma (DLC) and lymphoblastic lymphoma (LBL) were conducted between March 1989 and December 2004 by Kyushu-Yamaguchi Children's Cancer Study Group. Forty-two patients (DLC: 15, LBL: 27) and 34 patients (DLC: 8, LBL: 26) were enrolled in NHL-89 and NHL-96, respectively. DLC patients received induction therapy of high-dose methotrexate (MTX) followed by repeated administration of intermediate MTX. LBL patients received a 4-drug induction followed by intensification, consolidation with cranial radiotherapy (15 to 24Gy), and maintenance. The maintenance phase consisted of multiple drug treatment; including prednisolone, vincristine, cyclophosphamide, and 6-mercaptopurine. With a median follow-up of 150 months for NHL-89 and 90.5 months for NHL-96, the estimated event-free survival at 5 years are 76.2±6.6% and 67.7±8.0%, respectively. Both studies improved the prognosis of DLC and LBL over our previous study of NHL-858.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 53(11), 1898-1905, 2012-11-30

    The Japanese Society of Hematology

References:  19

Codes

  • NII Article ID (NAID)
    10031131256
  • NII NACSIS-CAT ID (NCID)
    AN00252940
  • Text Lang
    JPN
  • Article Type
    ART
  • ISSN
    04851439
  • NDL Article ID
    024121382
  • NDL Call No.
    Z19-295
  • Data Source
    CJP  NDL  J-STAGE 
Page Top